PROTACs use the natural garbage disposal machinery within cells to tag and remove problematic proteins, with potential applications ranging from cancer to pesticides.
CT-01 targets 3 well suited proteins including NEK7 with poor prognosis in key liver cancerStrong preclinical data generated with CT-02 against NEK7CT-05.
Captor Therapeutics Discloses Molecular Targets of Pipeline s Lead Assets and Invites Stakeholders to Webcast streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
10.08.2022 - WROCŁAW, Poland, Aug. 10, 2022 (GLOBE NEWSWIRE) - Captor Therapeutics S.A. (WSE:CTX), a biopharmaceutical company dedicated to the development of Targeted Protein Degradation (TPD)-based drugs for the treatment of cancer and autoimmune diseases, .
Captor Therapeutics to Host R&D Day on May 18, 2022 finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.